RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Clinical trials for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a single immunotherapy drug replace harsh Chemo-Radiation for head and neck cancer?
Disease control Recruiting nowThis study compares the immunotherapy drug pembrolizumab (Keytruda) against the usual combination of chemotherapy and radiation after surgery for head and neck cancer that has come back or is a new primary tumor. About 188 adults aged 18-79 with high-risk features (positive margi…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:20 UTC
-
New hope for Hard-to-Treat head and neck cancer: drug combo trial launches
Disease control Recruiting nowThis study tests whether adding cetuximab to the immunotherapy drug pembrolizumab helps people with advanced head and neck cancer live longer. The cancer has either come back or spread and no longer responds to platinum chemotherapy. About 158 adults will be randomly assigned to …
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New vaccine combo aims to fight recurrent head and neck cancer
Disease control Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor cells, alone or with the immunotherapy drug pembrolizumab, for head and neck cancer that has returned or spread. The goal is to find the safest dose and see if the vaccine helps the immune system …
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
Cholesterol drug boosts immunotherapy in head and neck cancer trial
Disease control Recruiting nowThis study tests whether adding the cholesterol-lowering drug lovastatin to the immunotherapy pembrolizumab can shrink tumors in people with head and neck cancer that has returned or spread. About 28 adults whose cancer has a specific marker (PD-L1 CPS≥1) will receive both drugs.…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated May 13, 2026 16:00 UTC
-
Could a Two-Drug punch before surgery beat head and neck cancer?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
New combo therapy aims to fight stubborn head and neck cancers
Disease control Recruiting nowThis early-phase trial is for people with head and neck cancer that didn't go away or came back after treatment. Researchers are testing whether giving immunotherapy (pembrolizumab) and radiation before and during surgery can kill more cancer cells. The main goal is to find out w…
Matched conditions: RECURRENT ORAL CAVITY SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated May 06, 2026 16:03 UTC